Adsorption capacity and percentage of total cholesterol(TC), LDL-C by cellulosic beads having different terminus groups. Source: Wang S Q et al, Reactive & Functional Polymers (2008), 68: 261-267
Cellulose, a natural polymer, has been widely used in blood purification due to its good biocompatibility, and excellent processing which can be easily formulated into beads, membranes and hollow fibers. Sorbent-perfusion is a novel approach of blood purification which can specifically remove endogenous and exogenous pathogenic toxins from the blood of patients . The technique involves passing whole blood or plasma of the patient through a cartridge filled with an adsorbent which can easily adsorb the toxin molecules, see
2. Preparation and activation of cellulosic beads
2.1. Preparation of cellulosic beads [10, 11]
One hundred grams of cotton (medical grade) was soaked in a flask containing 19% NaOH solution for 3 h at room temperature. The cotton was squeezed and weighed then placed in a 1500 ml conical flask at 25℃ for 3 days. Fifty milliliters of carbon disulfide was added to the conical flask which was then sealed and aged for 5 h to convert the cellulose into a viscose solution, which was then diluted to 1000 ml with 6% NaOH solution to make a 10% viscous solution of cellulose. In a reactor equipped with a stirrer, a mixture of 800 ml chlorobenzene, 200 ml carbon tetrachloride and 2.0 g of potassium oleate was stirred for 30 min at 300 rpm under room temperature. Then 300.0 ml of 10% cellulose viscose solution was added to the reactor slowly and continued stirring for 30 min until the liquid particles were dispersed uniformly. Thereupon, the temperature was slowly raised to 90℃ and kept for 2.5 h, after which it was cooled to room temperature to solidify the liquid particles into resin beads. Cellulosic beads were filtered (20–40 mesh) and washed thoroughly with alcohol and distilled water to remove all the impurities.
Compared to the gel type cellulosic beads, macroporous beads can greatly enhance the adsorption capacity for middle and high molecules in the therapeutic embolization of meningiomas [12-15]. It can be synthesized according to reference [16, 17]. In brief, a certain amount of pore-forming agent such as calcium carbonate granules, with an average diameter of about 0.2mm was added to a 10% viscous solution of cellulose, then mixed and dispersed to form cellulosic beads. After washing with dilute HCl to remove the pore-forming agent, various kinds of porous adsorbents could be prepared. Alternatively, macroporous cellulose beads could also be prepared from cellulose solution in ionic liquid by double emulsification [18, 19].
Recently, cellulosic microspheres with a particle size below 5μm have been widely adopted in blood purification [20, 21], which can be an excellent matrix for the preparation of adsorbent.
Bead porosity and density are calculated by the following equations: [10, 17]
Adsorption percentage and capacity can be calculated by the following equations,
2.2. Activation of cellulose beads
Cellulose can be easily activated by reaction with epichlorohydrin which is frequently used for the preparation of cellulosic adsorbent [10,22,23].Briefly, 10 grams of cellulosic beads was activated with 10ml epichlorohydrin in 20ml 2mol/l sodium hydroxide solution. The mixture was stirred at 40℃ for 4 h. Then the epoxy-activated cellulosic beads was washed thoroughly with distilled water and further reacted with amino acids or proteins, see
3. Mechanism study of molecular recognition between the ligand and the pathogenic toxic molecule.
3.1. Molecular recognition
To understand the interaction mechanism of pathogenic toxins with different ligands is essential, since it not only provides fundamental insight to biomaterial science, but also can lead to the discovery of more efficient ligands for the removal of pathogenic toxins in human blood. Chemical modification of proteins has been frequently used in the studies of structure-function relationships of proteins, especially in the determination of the active sites in biologically active proteins [23,24]. In the present study, we selectively modified the arginine, tryptophan, lysine residues and carboxyl terminus on the protein for the molecular recognition studies.
Lianyong Wang et al  investigated the interaction between ss- DNA and IgGRF by selectively modification of the arginine, tryptophan, lysine residues and carboxyl terminus on IgGRF, which was purified from patients’ serum. It is well known that the density of negative charge is high on the surface of ss-DNA molecule, due to the large amount of phosphate groups. After the ss-DNA was covalently attached to the cellulose carrier, the immunoadsorbent is negatively charged, so it has a high adsorption capacity for the positively charged
Shenqi Wang and Yaoting Yu et al  studied the mechanism of recognition and interactions of low density lipoprotein cholesterol（LDL-C） with different charged ligands on the adsorbents. Tryptophan, lysine residues and carboxyl terminus on LDL were chemically modified by PP，EDC and NBS respectively. Due to the effectiveness of L-lysine in the removal of LDL-C, it was selected to study the interaction of ligand with the modified LDL. Experimental results show that positive charge on the surface of LDL interacted with the negatively charged carboxyl groups of L-lysine by electrostatic force, thus resulting in the adsorption of LDL by the absorbent. We also found that increasing the positive charge on the surface of LDL could enhance the adsorption capacity of the adsorbent. On the contrary, increasing the negative charge could decrease the adsorption ability. Thus, different adsorbents containing sulfonic groups, phosphoric groups, L-lysine and carboxyl groups as the ligand were synthesized for investigating the effect of electric charge on their adsorption capacity. Results show that the adsorption capacity increases with the increase of the electro-negativity of the ligand on the adsorbent. See Table1
|Terminus group of adsorbent||TC||LDL-C|
|Adsorption percentage (%)||Adsorption capacity|
|Adsorption percentage (%)||Adsorption capacity|
Experimental results show that the adsorption capacity (mg/ ml or percentage) for TC and LDL-C decreased with decreasing of electro-negativity of ligands on the adsorbents (－SO32->－PO43->－COO-; －PO43->PP－PO43->DNA－PO43-), which demonstrate that the electro-negativity of ligand on adsorbent plays an important role in adsorbing TC and LDL-C. This relationship of the adsorption capacity to its electro-negativity is shown in Figure. 4
3.2. Spacer effect
Spacers have a significant effect on the adsorption property of the resin adsorbents. It can reduce the steric hindrance between the ligand and the large toxic molecules, resulting in an increase of adsorption capacity of the adsorbent. Different spacers have an obvious effect on the adsorption properties of adsorbents. The density of ligands on the carrier and the effect of steric hindrance are both important factors in specific adsorption. When the target substance is a small molecule, there may be no steric hindrance, see Figure 5 a, so the enhancement of the density of ligands can improve the adsorption capacity. But when the target substance is a large molecule, due to the presence of steric hindrance [26-33], a high density of ligands linked may display a low adsorption capacity of target protein, see
Note: a, Interaction between small target molecules and the immobilized ligands; b, Large target molecules having a steric hindrance to the immobilized ligands; c, Flexible spacer can reduce the steric hindrance,
In this study, carboxyl modified PEG spacer was synthesized and linked covalently to cellulose beads. L-lysine ligand was coupled to the spacer and its selective affinity for low-density lipoprotein-cholesterol (LDL-C) was determined. It was found that the adsorption capacity and the efficiency of the ligand for adsorption of LDL-C were increased when PEG spacer was used. Experimental results showed that by increasing the molecular weight of PEG spacers from 1000Da to 6000Da, the average adsorption capacity of LDL-C was enhanced from 0.242mg/ml to 0.903mg/ml. According to the analytical data of cellulose adsorbents, the amount of L-lysine ligand could be calculated. Although the amount of L-lysine linked to the adsorbent with PEG spacers (10.5, 9.8, 9.0, 8.6 mg per ml cellulose adsorbent respectively) was lower than those without PEG spacers (121.6mg per ml cellulose adsorbent), see Table 2, the average adsorption capacity for LDL-C per ml cellulose adsorbent increased from 0.130 mg/ml to 0.903 mg/ml. After the introduction of PEG spacers, (see Table 3) and consequently the adsorption capacity for LDL-C per unit ligand increased significantly from 0.001 mg/mg L-lysine to 0.105 mg/mg L-lysine, see Table 4, the adsorption capacity of LDL-C per unit L-lysine ligand (0.027mg LDL-C/mg L-lysine) was much higher than that without PEG spacer (0.001mg LDL-C/mg L-lysine). This result indicated that in the presence of PEG spacer, the adsorption efficiency of L-lysine ligands was enhanced significantly, see Table 5. It is postulated that appropriate increasing the amount of the L-lysine ligands and the use of PEG spacers can enhance the adsorption capacity for LDL-C.
|Molecular weight of PEG spacers (Da)||TC||LDL-C|
|Removal capacity (%)||Removal amount (mg/ml)||Removal capacity (%)||Removal amount (mg/ml)|
|Mol. weight of PEG spacers (Da)||L-Lysine amount (mg/ml)||Average removal amount of LDL－C (mg/ml)||Stoichiometric capacity (mg LDL-C/mg L-lysine)||Efficiency of active site (%)*|
|Mol .weight of PEG spacers (Da)||L-lysine amount (mg/ml)||Average removal capacity of LDL (mg/ml)||Stoichiometric capacity (mg LDL/mg L-lysine)||Efficiency of active site (%)*|
4. Typical bioactive bead type cellulosic adsorbent for blood purification
4.1. Cellulosic adsorbents for removing low density lipoprotein –cholesterol (LDL-C)
Familial hypercholesterolemia is characterized by a high concentration of plasma cholesterol in the form of low-density lipoprotein-cholesterol (LDL-C). In order to decrease the LDL-C level in patients, drugs and surgical intervention were reported . Sorbent-perfusion treatment is currently employed when the reduction of LDL-C level appears impossible to be achieved by drug administration [36-38]. Since the late 1970s, scientists have been engaged in developing different kinds of adsorbents to remove pathogenic substances [39-41].
Yaoting Yu and Shenqi Wang et al [42,43] have developed cellulosic adsorbent with amphiphilic ligands for the adsorption of (LDL-C) which was prepared by the following procedure: Cellulose beads were reacted with cholesterol N-(6-isocyanatohexyl) carbamate in the presence of pyridine in DMSO at 80℃ in order to introduce the hydrophilic moiety. It was then reacted with chlorosulfonic acid in dimethyl formamide to introduce the sulfonic group see Figure 6
The effects of sulfonation and grafting time of cholesterol on the swelling property of adsorbent were studied. Results showed that sulfonation and grafting time of cholesterol was 3 and 5 h, respectively. The amphiphilic adsorbent had a high adsorption capacity for LDL-C without significantly adsorbing high-density lipoprotein. Rabbit model was constructed according to the following method . In brief, Japanese white male rabbits were purchased from local experimental animal institute and housed in a standard facility. After feeding with standard chow and water
|Parameter||Before (mmol/l)||After (mmol/l)||Reduction (%)|
The authors also developed the adsorbent with lysine and phosphate groups as ligand for the treatment of hyperlipidemia [34, 45]. Comparing to the amphiphilic adsorbent, the adsorbent with lysine as ligand has a lower adsorption capacity for LDL-C, total cholesterol and higher HDL-C. On the other hand, the phosphalated cellulosic adsorbent has a higher adsorption capacity for LDL-C and lower for HDL-C, see Table 8.
|Before perfusion||After perfusion||Change=(A-B)/B×100%|
Haofeng Yu et al  synthesized PAA-grafted cellulosic adsorbent for the removal of LDL-C from human plasma. In-vitro studies showed that this adsorbent could remove total cholesterol (TC), LDL-C, and triglyceride (TG) at levels of 5.55, 4.46, and 2.48 mg /m1 respectively. Unfortunately, it removed 30% HDL-C in the plasma.
4.2. Cellulosic adsorbents for removal of rheumatoid factors
Rheumatoid Arthritis (RA) is a rather wide-spread immune disease. Spector reported that there is about 1% of the world's population is infected by this disease. Lianyong Wang and Yaoting Yu et al  covalently linked ss-DNA to cellulosic beads for the removal of rheumatoid factors. In vitro and in vivo studies showed that the adsorbent had a high adsorption capacity for IgMRF, IgGRF and IgARF, see Figure 7. Furthermore, the adsorbent attained good blood compatible properties.
Sorbent-perfusion using the above mentioned adsorbent was conducted on 35 RA patients clinically. Clinical protocol was designed as follows: 46 patients were hospitalized from Dec. 1998 until Nov.2000 and diagnosed as RA sickness. The extent of joint pain, swelling, morning stiffness, nodules under the skin, titer of rheumatoid arthritis factor (RF), value of immune-globulin and X-ray diagnosis of sick ankle etc. were all performed. The patients were divided into several groups from the above 46 patients. 35 of them matched the American Rheumatoid Arthritis Standard of 1987.
RA patients were graded into 4 grades according to the functional ability of the sick joint. 11cases having grade II joint sickness, 20 cases having grade III and 1 case having gradeIV. Conventional method of treatment was performed on 30 cases. The control group compared to treated group with a significance of P>0.05.
After perfusion the levels of rheumatoid factor was reduced and platelet count showed no significant changes in 35 RA patients (P<0.05) during treatment. After one week joint pain, swelling, tenderness, morning stiffness disappeared in 90 percent patients; 80 percent abnormal indexes recovered to normal value. After two to three weeks, joint function of 82 percent patients were improved and reached grade II or I. Two to three months later, X-ray examinations showed 80 percent bone matrix destruction was restored. Results of follow-up (0.67-2.5 years) proved that effective rate (97.14%, 81.25%) and total remission rate (82.86%, 59.38%) all had a significant improvement and recovery when compared to routine therapy.
In conclusion, clinical results show that sorbent-perfusion by cellulosic adsorbents is an effective approach for the therapy of rheumatoid arthritis. The treatment is safe, without hemolysis or pyrogenic side reactions, the adsorbent is easy to sterilize and cost effective.
4.3. Cellulosic adsorbents for removal of endotoxin
Bacterial endotoxins (ET), frequently named as lipopolysaccharides (LPS), are components of the outer cell wall of gram-negative bacteria and supposed to be a key factor in the pathogenesis of endotoxemia and septic shock [48,49]. Sorbent-perfusion is one of the best methods to remove endotoxin. Hui Fang and Yaoting Yu et al  synthesized a new type adsorbent for the removal of bacterial endotoxins by immobilizing lysine covalently onto cellulosic beads. Results showed that the adsorbent has good biocompatibility, see Table 9. In order to evaluate the adsorbent’s properties, rabbit models were constructed by the following method : Thirteen New Zealand white rabbits (weight 2.0-2.5 Kg) were injected intravenously with 0.20 mg LPS (
|Amount of coupled phosphate(µmol/ml)||0||68.4||94.3||128.6|
|Hemolysis||1.1% (standard <5% ),(n=3)|
|Platelet adhesion||18.76% (n=3) (10% is excellent; 10-30% is good)|
|Whole body toxicology||Wt. of rat before test Wt. of rat after test|
21.5±0.61 (g) 24.4±2.04 (g) (n=5)
|Allergic reaction||Grade 1, not higher than negative control (n=10), none allergic|
|Cytotoxicology||R* index of sample=0/0 (n=6), none toxic|
|Skin stimulation||PII**=0.0-0.4, (N=15), very mild toxic|
4.4. Cellulosic adsorbents for removal of anti-DNA antibody in treatment of systematic lupus erythematosus
The abnormally high levels of anti-DNA antibodies and immune complex in the sera of systemic lupus erythematosus (SLE) patients can be removed by sorbent- perfusion. Yaoting Yu and Deling Kong  synthesized cellulose adsorbents with DNA as ligand for the removal of anti-DNA antibodies. The activation of cellulosic beads were conducted according to reference : In brief, 2 ml of activated cellulose beads was added to 4.0ml buffer solution containing 4.0mg DNA in a flask and stirred at 25℃ for 20 h on a shaker. Then the immobilized DNA beads were washed consecutively with buffer solution and water, until no leakage of DNA in the rinse water was detected at 260nm by UV spectrometer. The immunoadsorbent thus obtained was stored at 4℃. In vitro adsorption tests showed that the DNA immuno-adsorbent could remove 40%-70% of anti-DNA antibody from plasma . The maximum decrease of anti-DNA level was 80% after 60 min in a dynamic experiment. This high adsorption capacity shows a high potential for clinical application.
4.5. Cellulosic adsorbent for the treatment of myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disorder characterized by a disturbance in neuromuscular transmission that results in muscle weakness. Yaoting Yu and Li Yang et al [51, 52] synthesized immobilized tryptophan cellulosic adsorbent and evaluated its adsorption capacity for binding acetylcholine receptor in the plasma of MG patients. Experimental autoimmune myasthenia gravis (EAMG) rabbits were induced by Ta183-200 peptide according to the following method: Briefly, Female rabbits weighing approximately 2 kg were injected intradermally at multiple sites with 500μg of T
The rabbits underwent extracorporeal whole blood perfusion for 2 h. Results showed no significant damages on blood cells and changes in the concentration of electrolytes. Whole blood sorbent-adsorption improved clinical manifestation and neuromuscular function of the EAMG rabbits, see Table 11
The neuromuscular transmission function was evaluated by the stimulation of the deep peroneal nerve. The mean decrement of potentials evoked from the anterior tibial muscle, at three stimulation frequencies in the therapeutic rabbit group were determined. At 3Hz, the potential decreased from 21.87% to 17.87%, at 5Hz, decreased from 22.25% to 18.75% and at 10 Hz, decreased from 24.37% to 23.25%. Table 12 shows the changes of the electro-physiological features of EAMG rabbits after WBIA which was on the 5th (D5) and the 8th (D8) day after passive transfer. The same RNS was performed in the control rabbit group, but no decrement was found, see Table 12
|No. of rabbits||Pre WBIA||5th day after WBIA|
|1||+||0 - +|
The quantity of neuromuscular junction can reflect the neurotransmission function. On the 3rd day after WBIA (D8), the quantity of neuromuscular junction per unit area (25mm2) of the therapeutic rabbit group was determined. Figure 11 shows the quantity of neuromuscular junction per unit area increased from 9.825±3.401 to 10.90±2.879(P<0.05) after WBIA, which was higher than that of the control group (P<0.01)
In conclusion, extracorporeal whole blood sorbent-adsorption is an effective and safe approach in treating the passive experimental autoimmune myasthenia gravis by improving clinical manifestation, neuromuscular transmission function, enhancing the quantity of neuromuscular junction and antibody titer.
5. Conclusion and future perspectives
Intensive research and development of cellulosic bead type adsorbents by sorbent-perfusion in blood purification have paved a path for the treatment of patients with autoimmune diseases, hyperlipidemia and inflammatory disorders. Animal experiments and clinical trials have proved that it is safe, efficient and cost effective. Therefore, it is highly potential to be used clinically on patients for upgrading the quality of their living standard and prolonging their survival rates.
The authors highly appreciate the financial support of Key project of National Basic Science and Development (G1999064707), the Project of 863（N0.2002AA326060）and Tianjin-Nankai University Co-Construction Foundation.
Behim E. Klinkmann H. 1989Selective and specific adsorbents for medical therapy. Int J Artif Organs. 12 1 10
Lupien P J. Moorjani S. Awad J. 1976 A new approach to the management of familial hypercholesterolaemia: removal of plasma cholesterol based on the principle of affinity chromatography, 1 1261 1265
Sinitsyn V V. Mamontova A G. Konovalov G A. Kukharchuk V V. 1990 Apheresis of low density lipoproteins using a heparin-based sorbent with low antithrombin III binding capacity 84 55 59
J M ( Maaskant N. Bantjes A. Kempen H. 1986 Removal of low density lipoprotein from blood plasma using cross-linked, sulfated polyvinylalcoholAtherosclerosis. 62 159 166
Kojima S. Harada-shiba M. Toyota Y. Kimura G. Tsushima M. Kuramochi M. Sakata T. Uchida K. Yamamoto A. Omae T. 1992 Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis.Int J Artif Organs. 15 185 190
Yatzidis H. 1964Research on extrarenal purification with the aid of activated charcoal. 72 310 312
Harbeck, Carr R I, Buffaloe G ( Terman D S. Petty D. 1977 Specific removal of DNA antibodies in vivo by extracorporeal circulation over DNA immobilized in collodion charcoalClin. Immunol. Immunopathol. 8 90 96
Falkenhagen D; Schima H; Loth F (in particular blood. United States Patent, #5,855,782. 1999Arrangement for removing substances from liquids
Von Appen K. Weber C. Losert U. Schima H. Gurland H J. Falkenhagen D. 1996 Microspheres based detoxification system: a new method in convective blood purification.Artif Organs 20 420 425
Fang H. Wei J. Yu Y T. 2004 In vivo studies of endotoxin removal by lysine-cellulose adsorbents.Biomaterilas. 25 5433 5440
Zhao Y P. Huang M S. Wu W. Jin W. 2009Synthesis of the cotton cellulose based Fe(III)-loaded adsorbent for arsenic(V) removal from drinking water. Desalination. 249 1006 1011
Kai Y. Hamada J-I. Morioka M. Yano S. Nakamura H. Makino K. Mizuno T. Takeshima H. Kuratsu J-I. 2006Clinical evaluation of cellulose porous beads for the therapeutic embolization of meningiomas. AJNR Am J Neuroadiol. 27 1146 1150
17 1895 1899 Hamada J, Ushio Y, Kazekawa K, Tsukahara T, Hashimoto N, Iwata H (1996) Embolization with cellulose porous beads I An experimental study. AJNR Am J Neuroradiol.17:1895-1899
Hamada J. Kai Y. Nagahiro S. Hashimoto N. Iwata H. Ushio Y. 1996 Embolization with cellulose porous beads II Clinical trial.Am J Neuroradiol. 17 1901 1906
Kai Y. Hamada J-I. Morioka M. Yano S. Nakamura H. Makino K. Mizuno T. Takeshima H. Kuratsu J-I. 2007Preoperative cellulose porous beads for therapeutic embolization of meninggioma:provocation test and technical considerations. Neuroradiology. 49 437 443
Wang D M. Hao G. Shi Q H. Sun Y. 2007 Fabrication and characterization of superporous cellulose bead for high-speed protein chromatographyJ Chromatogr A. 1146 32 40
Bai Y X. Li Y F. 2006 Preparation and characterization of crosslinked porous cellulose beadsCarbohyd Polym. 64 402 407
Du K F. Yan M. Wang Q Y. Song H. 2010 Preparation and characterization of novel macroporous cellulose beads regenerated from ionic liquid for fast chromatography.J Chromatogr A. 1217 1298 1304
Wang H F. Li B. Shi B L. 2008 Preparation and surface acid-base properties of porous cellulose 3 3 12
Thummler K. Fischer S. Feldner A. Weber V. Ettenauer M. Locth F. Faulkenhagen D. 2011Preparation and characterization of cellulose microspheres. Cellulose. 18 135 142
Weber V. Ettenauer M. Linsberger I. Loth F. Thummler K. Feldner A. Fisher S. Faukenhagen D. 2010Functionalization and application of cellulose microparticles as adsorbents inextracorporeal blood purification. Macomol.Symp. 294
Weber V. Linsberger I. Ettenauer M. Loth F. Hoyhtya M. Faulkenhagen D. 2005 Development of specific adsorbents for human tumor necrosis factor-a: Influence of antibody immobilization on performance and biocompatibility 6 1864 1870
Zhou H M. Wang H R. 1998Chemical Modification of Proteins. Beijing: Tsinghua University Press.19 p.
Wang S Q. Li C M. Guo X J. Yu Y T. Wang W C. 2008 Interaction Study of LDL with Charged Ligands for Effective LDL-C Removing AdsorbentsReact Funct Polym. 68 261 267
Wang L Y. Lu J. Yu Y T. 2004 Interaction of Rheumatoid Factor with Immobilized ss-DNAChem Res Chinese U. 20 795 800
Yang Y. 2002Agarose resin for removal of rheumatoid arthritis factors. Master thesis.
Hou K C. Zaniewski R. 1991 Protein A immobilized cartridge for immunoglobulin purification. Biotechnol. Appl. Bioc. 13 257 268
Adrian M. Roberto F-L. Jose M G. 2000 Essential role of the concentration of immobilized ligands in affinity chromatography: Purification guanidinobenzoatase on an ionized ligand. JChromatogr B. 740 211 218
Chu J Q. Zhang W H. Yu Y T. Zhu B R. Chen C Z. 2004 In vitro studies of the immunoadsorbent for removal of IgA-nephropathy(III). Chem JChinese U. 25 1454 1457
Leckband D E. Kuhl T. Wang H K. Herron J. Muller W. Ringsdorf H. 1995anti-fliorescyl IgG Fab’ recognition of membrane bpund hapten: direct evidence for the role of protein and interfacial structure. Biochemistry-US. 34 11467 11478
Zalipsky S. 1995Chemistry of polyethylene glycol conjugates with biological active molecules. Adv Drug Deliver Rev. 16 157 182
Harris M J. Struck C E. Case G M. Paley S M. Yalpanic M. Van Alstine M J. Brooks E D. 1984Synthesis and characterization of poly(ethylene glycol)derivatives. J Polym Sci. 22 341 352
Soltys J P. Etzel R M. 2000 Equilibrium adsorption of LDL and gold immunoconjugates to affinity membranes containing PEG Spacers. 21 37 48
Wang S Q. Guo X J. Wang L Y. Wang W C. Yu Y T. 2006 Effect of PEG Spacer on Cellulose Adsorbent for the Removal of Low Density Lipoprotein Cholesterol.Artif Cell Blood Subs. 34 101 112
Armstrong V W. Windisch M. Wieland H. Fuchs C. Rieger J. Kostering H. Nebendahl K. Scheler F. Seidel D. 1983Selective continuous extractacorporeal ekimination of low-density lipoprotein with heparin at acidic pH. Trans. Am Soc. Artif. Intern Organs. 29 323 327
In vitro study of a novel low density lipoprotein adsorbent ( Cao N N. Yu Y Y. Wang M Y. Chen C Z. 2002Artif Cell Blood Sub. 30 53 61
Sato Y. Agishi T. 1996Low-density lipoprotein adsorption for arteriosclerotic patients. Artif. Organs. 20 324 327
Chen B. Pan J L. Tong M R. Yu Y T. 1993A study of adsorbents for the adsorption of low density lipoprotein (LDL). Ion Exch Adsorption. 9 330 334
Sreenivasan K. 1997Synthesis and evaluation of cyclodextrin 2 hydroxyethy methacrylate copolymer as anovel adsorbent. Polym Int. 42 22 24
Bosch T. 1996Low density lipoprotein hemoperfusion using a modified polyacrylate adsorber:in vitro, exvitro and first clinical results. Artif Organs. 204 344 345
Bosch T. Schmidt B. Kleophas W. Gillen C. Otto V. Passlick-deetjen J. Gurland H J. 1997 LDL hemoperfusion-a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood.Artif Organs. 209 977 982
Wang S Q. Yu Y T. Cui T. Cheng Y. 2002 Cellulose amphiphilic adsorbent for the removal of low density lipoproteinArtif Cell Blood Subs. 30 285 292
Cheng Y. Wang S Q. Yu Y T. Yuan Y. 2003In vitro, in vivo studies of a new amphiphilic adsorbent for the removal of low-density lipoprotein. Biomaterials. 24 2189 2194
Chapman M J. 1980 Animal lipoproteins: chemistry, structure and comparative aspects.J Lipid Res. 21 789 853
Wang T. Wang W C. Wang L Y. Wei D. Wang S Q. Yu Y T. Kong D L. 2008 Phosphate-based affinity adsorbents for the removal of low density lipoprotein: Preparation and In vitro Adsorption capability testChinese J Biomed Eng. 27 132 136
Yu H F. Fu G Q. He B L. 2007 Preparation and adsorption properties of PAA-grafted cellulose adsorbent for low density lipoprotein from human plasma 14 99 107
Arnett F C. Edworthy S M. Bloch D A. Mcshane D J. Fries J M. Cooper N S. Healey L A. Kaplan L A. Liang M H. Luthra H S. Medsger T A. Mitchell D A. Neustadt D H. Pinals R S. Schaller J G. Sharp J T. Wilder R. Hunder G G. 1988The 1987 revised ARA criteria for rheumatoid arthritis Rheum. Arthritis and Rheumatism. 31 315 324
R H. Biochemistry of endotoxins ( Raetz C. 1990Annu Rev Biochem. 59 129 170
Callery M P. Kamei T. Mangino M J. Flye M W. 1991 Organ interactions in sepsis. Host defense and the hepatic-pulmonary macrophage axis.Arch Surg-Chicago. 126 28 32
Kong D L. Chen C Z. Lin E F. Yu Y T. 1998Clinical trials of type I and invitro studies of type? immunoadsorbents for systemic lupus erythematosus therapy. Artif Organs. 22 644 650
Yang L. Cheng Y. Yan W R. Yu Y T. 2004 Extracorporeal whole blood immunoadsorption of autoimmune myasthenia gravis by cellulose tryptophan adsorbent.Artif Cell Blood Sub. 32 519 528
Li X H. Cheng Y. Yang L. Wang S Q. Yu Y T. 2010Extracorporeal whole blood immune-adsorption of passively transferred myasthenia gravis rabbits by cellulose-tryptophan column. Artif Cell Blood Sub. 38 186 191